Cover Feature: Altering the Modular Architecture of Galectins Affects its Binding with Synthetic α‐Dystroglycan O‐Mannosylated Core M1 Glycoconjugates In situ (ChemBioChem 14/2023)

Abstract

Seek a cell anchorage galectin bridge: Transforming the wildtype Galectin (Gal)-1 and -3 to a tandem-repeat type variant via rational protein engineering enhanced cis-binding activity with O-Mannosylated core M1 glycopeptides of α-dystroglycan (DG). Furthermore, the Gal-1 variants (but not Gal-3 variants) demonstrated trans-bridging activity with the prepared α-DG core-M1 glycoconjugates and laminins in situ via the carbohydrate-protein interactions. Thus, Gal-1 and its variants are exciting candidates for treating several forms of muscular dystrophy. More information can be found in the Research Article by H. Kaltner, H. Hinou, et al.